McKelligon Brian's Form 4 filing
Akoya Biosciences, Inc. (AKYA) · filed Jun 12, 2024
- Accession no.
- 0001104659-24-070825
- Filed
- Jun 12, 2024, 4:01 PM ET
- Trade date
- Jun 11, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $15.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McKelligon BrianCIK 0001857447 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | Common Stock | MOption exerciseAcquired | +7,500 | $0.303 | +$2,272.5 | 232,233 | Direct | |
| Jun 11, 2024 | Common Stock | SSaleDisposed | −7,500 | $2.08 | −$15,630 | 224,733 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 275,629 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.